Precision Medicine: Genomic Profiles to Individualize Therapy

Otolaryngologic Clinics of North America

Volumn 50, Issue 4, 2017, Pages 765-773

  Streeter, Oscar E ^a   Beron, Phillip J ^b   Iyer, Prashant Natarajan ^c  

^a The Center for Thermal Oncology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ORACLE CORPORATION   (United States)

Author keywords

Big data; Checkpoint inhibitors; Genomic profiling; Hyperthermia; Immunotherapy; Machine learning; Precision medicine; Radiogenomics

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER PATIENT; GENOMICS; HEAD AND NECK CANCER; HEALTH CARE; HUMAN; HYPERTHERMIA; INFORMATION PROCESSING; INFORMATION TECHNOLOGY; MACHINE LEARNING; PATIENT CARE; PERSONALIZED MEDICINE; RADIOGENOMICS; REVIEW; CLINICAL DECISION MAKING; COMPUTER ASSISTED THERAPY; GENETIC MARKER; HEAD AND NECK TUMOR; IMMUNOTHERAPY; OUTCOME ASSESSMENT; PROCEDURES; STATISTICAL ANALYSIS;

CLINICAL DECISION-MAKING; DATA INTERPRETATION, STATISTICAL; GENETIC MARKERS; GENOMICS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MACHINE LEARNING; OUTCOME ASSESSMENT (HEALTH CARE); PRECISION MEDICINE; THERAPY, COMPUTER-ASSISTED;

EID: 85020119360     PISSN: 00306665     EISSN: 15578259     Source Type: Journal    
DOI: 10.1016/j.otc.2017.03.012     Document Type: Review

References (15)

1. Oracle Health Sciences. Precision medicine: providing the right therapy to the right patient at the right time. 2016. Available at: http://www.oracle.com/us/industries/health-sciences/precision-medicine-info-2692756.pdf. Accessed October 1, 2016.
2. Green, E.D., Guyeer, M.S., National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature 470:7333 (2011), 204–213.
3. Mohamed, A.N., Pemberton, P., Zonder, J., et al. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res 9:4 (2003), 1333–1337.
4. Aparicio, S., Caldas, C., The implications of clonal genome evolution for cancer medicine. N Engl J Med 368:9 (2013), 842–851.
5. Beltran, H., Eng, K., Mosquera, J.M., et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol 1:4 (2015), 466–474.
6. National Cancer Institute. NCI-MATCH: targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphomas (ClinicalTrials.gov Identifier: NCT02465060). 2015. Available at: https://clinicaltrials.gov/ct2/results?term=nct02465060. Accessed September 28, 2016.
7. Lalami, Y., Awada, A., Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treat Rev 43 (2016), 113–123.
8. Ferris, R.L., Immunology and immunotherapy of head and neck cancer. J Clin Oncol 33:29 (2015), 3293–3304.
9. West, H., Immune checkpoint inhibitors. JAMA Oncol, 1(1), 2015, 115.
10. Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32:6 (2014), 579–586.
11. Economopoulo, P., Agelaki, S., Perisanidis, C., et al. The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol 27:9 (2016), 1675–1685.
12. Valdagni, R., Amichetti, M., Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therappy plus hyperthermia to metastatic lymph nodes in Stage IV head and neck patients. Int J Radiat Oncol Biol Phys 28:1 (1994), 163–169.
13. Toraya-Brown, S., Fiering, S., Local tumor hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia 30:8 (2014), 531–539.
14. Trifiletti, D.M., Showaalter, T.N., Big data and comparative effectiveness research in radiation oncology: synergy and accelerated discovery. Front Oncol 5:274 (2015), 1–5.
15. Obermeyer, Z., Emanuel, E.J., Predicting the future - big data, machine learning, and clinical medicine. N Engl J Med 375:13 (2016), 1216–1219.